Current and potential applications of pharmacogenetics and pharmacogenomics in the treatment of psoriasis

Moderate-to-Severe Psoriasis, Third Edition

Volumn , Issue , 2008, Pages 379-392

  Hinchman, Kristy F ^a   Liao, Wilson ^b   Koo, John Y M ^b   Wu, Jashin J ^a  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84869794958     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (81)

1. Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004; 9(2): 136-139.
2. Feldman SR, Fleischer AB, Reboussin DM Jr, et al., The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997; 37:564-569.
3. Griffiths CEM, Clark CM, Chalmers RJG, et al. A systematic review of treatments for severe psoriasis. Monograph 2000; 4: 1-124.
4. Myers WA, Gottlieb AB, Mease P. Psoriasis and psoriatic arthritis: Clinical features and disease mechanisms. Clin Dermatol 2006; 24: 438-447.
5. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: Epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64: ii14-ii17.
6. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007; 445: 866-873.
7. Spuls PI, Bossuyt PM, van Everdingen JJ, et al. The development of practice guidelines for the treatment of severe plaque form psoriasis. Arch Dermatol 1998; 134: 1591-1596.
8. Tagami H. Triggering factors. Clin Dermatol 1997; 15: 677-685.
9. Oestreicher JL, Walters SIB, Kikuchi T, et al. Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. Pharmacogenomics J 2001; 1: 272-287.
10. Farber EM, Nall L, Watson W. Natural history of psoriasis in 61 twin pairs. Arch Dermatol 1974; 109: 207-211.
11. Elder JT, Nair RP, Guo SW, et al. The genetics of psoriasis. Arch Dermatol 1994; 130: 216-224.
12. Bowcock AM, Krueger JG. Getting under the skin: The immunogenetics of psoriasis. Nature Rev Immunol 2005; 5: 699-711.
13. Sagoo GS, Tazi-Ahnini R, Barker JW, et al. Meta-analysis of genome-wide studies of psoriasis susceptibility reveals linkage to chromosomes 6p21 and 4q28-q31 in Caucasian and Chinese Hans population. J Invest Dermatol 2004; 122: 1401-1405.
14. Enerback C, Martinsson T, Inerot A, et al. Evidence that HLA-Cw6 determines early onset psoriasis, obtained using sequence-specific primers (PCR-SSP). Acta Derm Venerol 1997; 77(4): 273-276.
15. Nair RP, Stuart PE, Nistor I, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 2006; 78: 827-851.
16. Elder JT. PSORS1: Linking genetics and immunology. J Invest Dermatol 2006; 126: 1205-1206.
17. Mallon E, Bunce M, Savoie H, et al. HLA-C and guttate psoriasis. Br J Dermatol 2000; 143: 1177-1182.
18. Bhalerao J, Bowcock AM. The genetics of psoriasis: A complex disorder of the skin and immune system. Hum Molec Genet 1998; 7(10): 1537-1545.
19. Tomfohrde J, Silverman A, Barnes R, Fernandez-Vina MA, Young M, Lory D, Morris L, Wuepper KD, Stastny P, Menter A, et al. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 1994; 264: 1141-1145.
20. Hwu WL, Yang CF, Fann CS, Chen CL, Tsai TF, Chien YH, Chiang SC, Chen CH, Hung SI, Wu JY, Chen YT, et al. Mapping of psoriasis to 17q terminus. J Med Genet 2005; 42: 152-158.
21. Yang CF, Hwu WL, Yang LC, et al. a promoter sequence variant of ZNF750 is linked with familial psoriasis. J Invest Dermatol 2008; 128: 1662-1668.
22. Henseler T, Christophers E. Psoriasis of early and late onset; characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985; 13: 450-456.
23. Henseler T. The genetics of psoriasis. J Am Acad Dermatol 1997; 37: S1-S11.
24. Nair RP, Ruether A, Stuart PE, et al. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Investig Dermatol 2008; 128: 1653-1661.
25. Cargill M, Schrodi SJ, Chang M, et al. A large scale genetic association study confirms IL-12 and leads to IL-23R as psoriasis-risk genes. Am J Hum Genet 2007; 80: 273-290.
26. Hollox EJ, Huffmeier U, Zeeuwen PLJM, et al. Psoriasis is associated with increased β-definsin genomic copy number. Nature Genetics 2008; 40(1): 23-25.
27. Lesueur F, Oudot T, Heath S, et al. ADAM 33, a new candidate for psoriasis susceptibility. PLoS ONE 2007; 2(9): e906.
28. Siroux V, Bouzigon E, Dizier M-H, et al. Replication of association between ADAM33 polymorphisms and psoriasis. PLoS ONE 2007; 3(6): e2448.
29. Smith RL, Warren RB, Eyre S, et al. Polymorphisms in the PTPN22 region are associated with psoriasis of early onset. British J of Dermatol 2008; 158: 962-968.
30. Capon F, Bijilmakers M-J, Wolf N, et al. Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene. Hum Mol Genet 2008; 17: 1938-1945.
31. GAIN Collaborative Research Group. New models of collaboration in genome-wide association studies: The Genetic Association Information Network. Nat Genet 2007; 39(9): 1045-1051.
32. Rosman M, Bertino JR. Azathioprine. Ann Intern Med 1973; 79: 694-700.
33. Wise M, Callen JP. Azathioprine: A guide for the management of dermatology patients. Dermatol Ther 2007; 20: 206-215.
34. Patel AA, Swerlick RA, McCall CO. Azathioprine in dermatology: The past, the present, and the future. J Am Acad Dermatol 2006; 55: 369-389.
35. Oh KT, Anis AH, Bae SC. Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction from treatment of azathioprine in Korea. Rheumatology 2004; 43: 156-163.
36. Gabbani G, Pavanello S, Nardini B, et al. Influence of metabolic genotypes GSTM1 on levels of urinary mutagens in patients treated topically with coal tar. Mutat Res 1999; 440: 27-33.
37. Kragballe K, Gjertsen BT, De Hoop D, et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991; 337: 193-196.
38. Smith EL, Walworth NC, Holick MF. Effect of 1,25-dihydroxyvitamin D3 on the morphological and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dermatol 1986; 86: 709-714.
39. Deluca HF, Cantorna MT. Vitamin D: Its role and uses in immunology. FASEB J 2001; 15: 2579-2585.
40. Mathieu C, Adorini L. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulary agents. Trends Mol Med 2002; 8: 174-179.
41. Chen ML, Perez A, Sanan DK, et al. Induction of vitamin D receptor mRNA expression in psoriatic plaques correlates with clinical response to 1,25-dihydroxyvitamin D3. J Invest Dermatol 1996; 106: 637-641.
42. Giomi B, Ruggiero M, Fabbri M, et al. Does the determination of the Bb vitamin D receptor genotype identify psoriasis vulgaris patients responsive to topical tacalcitol? J Dermatol Science 2005; 37: 180-181.
43. Li C, Liu Z, Zhang Z, et al. Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. J Invest Dermatol 2007; 127(2): 276-280.
44. Van Dooren-Greebe R, Kuijpers A, Mulder J, et al. Methotrexate revisited: Effects of long-term treatment in psoriasis. Br J Dermatol 1994; 130: 204-210.
45. Grosflam J, Weinblatt ME. Methotrexate: Mechanism of action, pharmacokinetics, clinical indications and toxicity. Curr Opin Rheumatol 1991; 3: 363-368.
46. Goldman ID, Matherly LH. The cellular pharmacology of methotrexate. Pharmacol Ther 1985; 28: 77-102.
47. Rozen R. Molecular genetics of methylenetetrahydrofolate reducatase deficiency. J Inherit Metab Dis 1996; 19: 589-594.
48. van Ede AE, Laan RF, Blom HJ, et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: A genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 2001; 11: 2525-2530.
49. Gabreels F, Stevens EM, Smeitink JA, et al.Asecond common mutation in methylenetetrahydrofolate reductase gene: An additional risk factor for neural tube defects? Am J Hum Genet 1998; 62:1044-1045.
50. Winegard S, Weisberg I. A second genetic polymorphism in methyltetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Circ Res 1998; 83: 60-72.
51. Kumagai K, Hiyama K, Oyama T. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med 2003; 11: 593-600.
52. Campalani E, Arenas M, Marinaki AM, et al. Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J Investig Dermatol 2007; 127: 1860-1867.
53. Lim KK, Su WPD, Schroeter AL, et al. Cyclosporine in the treatment of dermatologic disease: An update. Mayo Clin Proc 1996; 71: 1182-1191.
54. Saeki T, Ueda K, Tangigawara Y, et al. Human P-glycoprotein transports cyclosporine A and FK506. J Biol Chem 1993; 268: 6077-6080.
55. Kuehl P, Zhang J, Lu Y, et al. Sequence diversity in CYP 3A promoters and characterization of the genetic basis of polymorphic CYP 3A5 expression. Nat Genet 2001; 27: 383-391.
56. Ozdemir V, Kalowa, Tang BK, et al. Evaluation of the genetic component of variability in CYP 3A4 activity: A repeated drug administration method. Pharmacogenetics 2000; 10: 373-388.
57. Anglicheau D, Thervet E, Etienne I, et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004; 75: 422-433.
58. Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74(3): 245-254.
59. Foote CJ, Greer W, Kiberd BA, et al. MDR1 C3435T Polymorphisms correlate with cyclosporine levels in de novo renal recipients. Transplant Proc 2006; 38: 2847-2849.
60. Diaz BV, Lenoir MC, Ladoux A, et al. Regualtion of vascular endothelial growth factor expression in human keratinocytes by retinoids. J Biol Chem 2000; 275: 642-650.
61. Brenchley PEC. Angiogenesis in inflammatory joint disease: A target for therapeutic intervention. Clin Exp Immunol 2000; 121: 426-429.
62. Detmar M, Brown LF, Claffey KP, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994; 180: 1141-1146.
63. Young HS, Summers AM, Read IR, et al. Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Investig Dermatol 2006; 126: 453-459.
64. Vasku V, Vasku JB, Goldbergova MP, et al. Three retinoid X receptor gene polymorphisms in plaque psoriasis and psoriasis guttata. Dermatology 2007; 214: 118-124.
65. Krueger GG. Selective targeting of T-cell subsets: Focus on alefacept-a remittive therapy for psoriasis. Expert Opinin Biol Ther 2002; 2: 431-441.
66. Haider AS, Lowes MA, Gardner H, et al. Novel insight into the agonistic mechanism of alefacept in vivo: Differentially expressed genes may serve as biomarkers of response in psoriasis patients. J Immunol 2007; 178(11)7442-7449.
67. Cather JC, Cather JC, Menter A. Modulating T-cell responses for the treatment of psoriasis: A focus on efalizumab. Expert Opin Biol Ther 2003; 3: 361-370.
68. Gordon KB, Papp KA, Hamilton TK, et al. for the Efalizumab Study Group. Efalizumab for patients with moderate to severe plaque psoriasis. JAMA 2003; 290: 3073-3080.
69. Lebwohl M, Tyring SK, Hamilton TK, et al, for the Efalizumab Study Group. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349: 2004-2013.
70. Bonnekoh B, Pommer AJ, Bockelmann R, et al. Topo-proteonomic in situ analysis of psoriatic plaque under efalizumab treatment. Skin Pharmacol Physiol 2007; 20(5)237-252.
71. Tutuncu Z, Kavanaugh A, Zvaifler N, et al. Fc-gamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum 2005; 52(9): 2693-2696.
72. Seitz M, Wirthmuller U, Moller B, et al. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNF-alpha-blockers in rheumatoid arthritis and spondyloarthritits patients. Rheumatology 2007; 46(1): 93-96.
73. Miceli-Richard C, Comets E, Verstuyft C, et al.Asingle tumor necrosis factor haplotype influences response to adalimumab in rheumatoid arthritis. Ann Rheum Dis 2007; doi:10.1136/ard.2007.074104.
74. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL 12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13: 715-725.
75. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin-23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004; 199: 125-130.
76. Hunter CA. New IL-12 family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005; 5: 521-531.
77. Bowman EP, Chackerian AA, Cua DJ. Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy. Curr Opin Infect Dis 2006; 19: 245-252.
78. Tsunemi Y, Saeki H, Nakamura K, et al. Interleukin-12 p40 gene (IL12B) 3'-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris. J Dermatol Sci 2002; 30: 161-166.
79. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356: 580-592.
80. Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006; 203: 2577-2587.
81. Gottlieb AB, Cooper KD, McCormick TS, et al. A phase 1, double-blind, placebocontrolled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin 2007; 23(5): 1081-1092.